Third dose of BNT162b2 COVID-19 vaccine effective at decreasing risk of hospitalization
1. Compared to two doses of the BNT162b2 vaccine, a third booster dose was estimated to be 93% effective against ...
Tag: vaccine
#VisualAbstract: Adequate antibody response to mRNA-1273 COVID-19 vaccine occurs in patients with cancer
1. The majority of patients being treated for solid tumour cancers were adequate responders to the vaccine. 2. Serious adverse ...
Risk of Guillain-Barré Syndrome following recombinant zoster vaccine in medicare beneficiaries
1. In a cohort of Medicare beneficiaries, the recombinant zoster vaccine was associated with a slightly increased risk of Guillain-Barré ...
Risk prediction of COVID-19 related death and hospital admission in adults after COVID-19 vaccination
1. Out of 5,150,310 individuals in England that received two COVID-19 vaccine doses, 81 patients passed away from COVID-19 and 71 were ...
Routine childhood vaccinations disrupted by the 2020 global pandemic
1. Approximately 8.5 million children were estimated to have missed DTP3 and MCV1 vaccinations in 2020 due to the global ...
COVID-19 vaccinations during pregnancy: coverage and safety
1. In a cohort of pregnant women in the United Kingdom, COVID-19 vaccines did not alter perinatal outcomes. Evidence Rating ...
#VisualAbstract: Novel malaria vaccine candidate (R21/MM) is safe and highly protective against malaria transmission in African children
1. Vaccine efficacy at 6 months for R21/MM was 74% in group 1 and 77% in group 2. 2. R21/MM showed ...
Nationwide vaccination campaign with BNT162b2 (Pfizer–BioNTech) mRNA vaccine reports high immunogenicity across all age groups
1. There was a vaccine efficacy of 97.2% against symptomatic COVID-19 infection in individuals at least 7 days after their ...
#VisualAbstract: BNT162b2 mRNA vaccine shows benefit against symptomatic and asymptomatic SARS-CoV-2 infection
1. Vaccinated individuals reported fewer SARS-CoV-2 infections and a lesser proportion of cases were symptomatic compared to the unvaccinated cohort. ...
BNT162b2 mRNA vaccine shows benefit against symptomatic and asymptomatic SARS-CoV-2 infection
1. Vaccinated individuals reported fewer SARS-CoV-2 infections and a lesser proportion of cases were symptomatic compared to the unvaccinated cohort. ...